Advanced Oncotherapy – Interim Results A Horror Show
By Nigel Somerville, the Deputy Sheriff of AIM | Saturday 1 October 2022
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
AIM-listed Advanced Oncotherapy released its interim results to June 2022 this morning – deadline day (never a good sign). The numbers are horrific – and so it seems are the prospects!
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.